Drugs / davoceticept
davoceticept
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04920383 | Jun 2021 → Nov 2022 | lymphoma | Alpine Immune Sciences, Inc. | Terminated | No outcome recorded Stop: Business |
| Phase 1 | NCT04186637 | Jun 2020 → Nov 2022 | lymphoma | Alpine Immune Sciences, Inc. | Terminated | No outcome recorded Stop: Business |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | davoceticept | “davoceticept (ALPN-202), a PD-L1-dependent CD28 costimulator and dual PD-L1/CTLA-4 checkpoint inhibitor, in combination with pembrolizumab” PMID 39142718 ↗ Aug 20241“Phase I studies of davoceticept (ALPN-202), a PD-L1-dependent CD28 co-stimulator” PMID 39097413 ↗ Aug 2024 |
| Known as | ALPN-202 | “davoceticept (ALPN-202), a PD-L1-dependent CD28 costimulator and dual PD-L1/CTLA-4 checkpoint inhibitor, in combination with pembrolizumab” PMID 39142718 ↗ Aug 20241“Phase I studies of davoceticept (ALPN-202), a PD-L1-dependent CD28 co-stimulator” PMID 39097413 ↗ Aug 2024 |
| Known as | Vigd | ChEMBL registry synonym — accepted as the source's own label CHEMBL5095305 ↗ |
| Action | Inhibit | “while inhibiting the PD-L1 and cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) checkpoints.” PMID 39097413 ↗ Aug 2024 |
| Modality | Protein / enzyme biologic | “Davoceticept (ALPN-202) is an Fc fusion of a CD80 variant immunoglobulin domain” PMID 39097413 ↗ Aug 2024 |
| Route | Intravenous | “davoceticept 0.001-10 mg/kg was administered intravenous” PMID 39097413 ↗ Aug 2024 |